Evidence map›Paper›PMID 27312405›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2016

The Effects of Pharmacological Opioid Blockade on Neural Measures of Drug Cue-Reactivity in Humans.

Kelly E Courtney, Dara G Ghahremani, Lara A Ray

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. FMRI-based prediction of naltrexone response in alcohol use disorder: a replication study.European archives of psychiatry and clinical neuroscience · 2021
    Article
  11. A Scoping Review on Cue Reactivity in Methamphetamine Use Disorder.International journal of environmental research and public health · 2020
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kelly E CourtneyDepartment of Psychology, University of California, Los Angeles, CA, USA.
Dara G GhahremaniDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Lara A RayDepartment of Psychology, University of California, Los Angeles, CA, USA.

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
UCLA Training Program in Translational Neuroscience of Drug Abuse (TNDA)T32DA024635 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY, Kate M Wassum · 2008 to 2026
$6.2M
Pharmacogenetics of Natlrexone for Methamphetamine Use DisorderR21DA029831 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAY, LARA A. · 2011 to 2013
$478k
The Effects of Naltrexone on Neural Responses to Methamphetamine CuesF31DA035604 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI COURTNEY, KELLY ELIZABETH · 2013 to 2014
$66k
NCATS NIH HHS UL1 TR000124NIDA NIH HHS F31 DA035604NIDA NIH HHS R21 DA029831NIDA NIH HHS T32 DA024635
6 · The paper itself

Abstract

Interactions between dopaminergic and opioidergic systems have been implicated in the reinforcing properties of drugs of abuse. The present study investigated the effects of opioid blockade, via naltrexone, on functional magnetic resonance imaging (fMRI) measures during methamphetamine cue-reactivity to elucidate the role of endogenous opioids in the neural systems underlying drug craving. To investigate this question, non-treatment seeking individuals with methamphetamine use disorder (N=23; 74% male, mean age=34.70 (SD=8.95)) were recruited for a randomized, placebo controlled, within-subject design and underwent a visual methamphetamine cue-reactivity task during two blood-oxygen-level dependent (BOLD) fMRI sessions following 3 days of naltrexone (50 mg) and matched time for placebo. fMRI analyses tested naltrexone-induced differences in BOLD activation and functional connectivity during cue processing. The results showed that naltrexone administration reduced cue-reactivity in sensorimotor regions and related to altered functional connectivity of dorsal striatum, ventral tegmental area, and precuneus with frontal, visual, sensory, and motor-related regions. Naltrexone also weakened the associations between subjective craving and precuneus functional connectivity with sensorimotor regions and strengthened the associations between subjective craving and dorsal striatum and precuneus connectivity with frontal regions. In conclusion, this study provides the first evidence that opioidergic blockade alters neural responses to drug cues in humans with methamphetamine addiction and suggests that naltrexone may be reducing drug cue salience by decreasing the involvement of sensorimotor regions and by engaging greater frontal regulation over salience attribution.

Indexed as

Brain MappingCuesAdultBehavior, AddictiveBrainCentral Nervous System StimulantsFemaleHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMethamphetamineNaltrexoneNarcotic AntagonistsOxygenSubstance-Related DisordersCentral Nervous System StimulantsMethamphetamineNaltrexoneNarcotic AntagonistsOxygen

Identifiers

PMID27312405
PMCPMC5061897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.